Total Funding
91
96
Total FundingPost-IPO Debt raised
Growth Score
4 pts
Heat Score
33 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
413
Nyxoah is a medical device company focused on the development and commercialization of a hypoglossal nerve stimulation (HGNS) therapy.
- John Landry: CFO
- Maurits Boon: Chief Medical Officer
About the Company
Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common
sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
